Hummingbird and Merck to evaluate combination therapy for NSCLC

Hummingbird and Merck to evaluate combination therapy for NSCLC

Submitted by admin on May 15, 2023 - 6:19pm
Source: 
Clinical Trials Arena
News Tags: 
Merck
Hummingbird Bioscience
HMBD-001
cetuxumab
squamous non-small cell lung cancer
Headline: 
Hummingbird and Merck to evaluate combination therapy for NSCLC
snippet: 

Singapore-based biotechnology company Hummingbird Bioscience has partnered with Merck to evaluate its HER3-targeting antibody HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma (sqNSCLC).

Do Not Allow Advertisers to Use My Personal information